ImegenImegen

  • Twitter
  • Facebook
  • YouTube
  • LinkedIn
  • en 
  • es 
Cáncer hereditario
Customer area
  • Products and Services
    • Prenatal stage
      • Non-Invasive Prenatal Test
      • Prenatal diagnosis
      • Prenatal diagnosis of a rare disease
    • Pediatric stage
      • Neuropaediatric disorders
      • Genetic syndromes
      • Diagnosis of rare diseases
    • Adult stage
      • Diagnosis of rare diseases
      • Reproductive screening
      • Cancer
    • IMEXOME
    • Kits for analysis
  • Hospitals and Specialists
    • Kits for analysis
    • Techniques available
  • Patients and Families
    • Genetic guide
    • Non-Invasive Prenatal Test
  • R&D
    • Partner profile
    • R&D projects
  • About us
    • About us
    • Team
    • Excellent quality
HomeProducts and ServicesAdult stageCancer

Cancer

Cancer is a multifactorial disease in which both genetic and environmental factors play a role. The early detection of a tumour and its correct classification allows access to a targeted therapy that is specific for each tumour.

Around 5-10% of cancer cases are hereditary. Identification of the molecular cause of such cancers using genetic diagnosis allows the family risks to be estimated and the preventive measures or treatments available to be established.

Find your genetic test
Advanced search

Specific tools

IMEGEN has developed a series of specific tools based on the analysis of a large number of genes associated with the most common types of cancer:

Hereditary cancer

Detection of hereditary genetic alterations in genes directly associated with an increase in the susceptibility to certain types of cancer. A good example of this is the mutations in the genes BRCA1 and BRCA2 found in hereditary breast and ovarian cancer.

Somatic cancer

Detection of biomarkers associated with different types of tumour that allow access to specific treatments for each tumour. One example of this is the alterations to the genes KRAS and BRAF found in the therapeutic management of colorectal cancer. The therapy, dose and treatment efficacy of these types of cancer are governed by the presence or absence of such genetic markers.

Request Information

Please fill out the form below to request any information about our products and services, or call us at  +34 963 212 340.

Name
Company
Phone
E-mail
Message

Acept legal conditions

I understand and accept this Privacy Policy by checking this box

I consent the use of my personal data to receive publicity of your entity YesNo

Customer area

I forgot my password New user Close

Instituto de Medicina Genómica, S.L.

Founded in 2009 by a team of scientists with more than 20 years’ business experience, it has since grown to become the leader in the genetics and genomics sector.

Meet Imegen

  • Products and Services
    • Prenatal stage
      • Non-Invasive Prenatal Test
      • Prenatal diagnosis
      • Prenatal diagnosis of a rare disease
    • Pediatric stage
      • Neuropaediatric disorders
      • Genetic syndromes
      • Diagnosis of rare diseases
    • Adult stage
      • Diagnosis of rare diseases
      • Reproductive screening
      • Cancer
    • IMEXOME
    • Kits for analysis
  • Hospitals and Specialists
    • Kits for analysis
    • Techniques available
  • Patients and Families
    • Genetic guide
    • Non-Invasive Prenatal Test
  • R&D
    • Partner profile
    • R&D projects
  • About us
    • About us
    • Team
    • Excellent quality

Contact

c/ Agustín Escardino 9, Parc Científic de la Universitat de València - 46980 Paterna

info@imegen.es
Tel: +34 963 212 340

Empresa cofinanciada por:
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy